• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

    Thumbnail
    View/ Open
    oncotarget-08-23213.pdf (11.04Mb)

    Show full item record
    
    Author
    Ultimo, Simona; Simioni, Carolina; Martelli, Alberto M.; Zauli, Giorgio; Evangelisti, Camilla; Celeghini, Claudio; McCubrey, James A.; Marisi, Giorgia; Ulivi, Paola; Capitani, Silvano; Neri, Luca M.
    Abstract
    B-acute lymphoblastic leukemia (B-ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. Philadelphia chromosome-positive (Ph+) B-ALL is a subtype that expresses the Bcr-Abl fusion protein which represents a negative prognostic factor. Constitutive activation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) network is a common feature of B-ALL, influencing cell growth and survival. In the present study, we aimed to investigate the efficacy of PI3K isoform inhibition in B-ALL cell lines harboring the Bcr-Abl fusion protein. We studied the effects of anti Bcr-Abl drugs Imatinib, Nilotinib and GZD824 associated with PI3K isoform inhibitors. We used a panel of six compounds which specifically target PI3K isoforms including the pan-PI3K inhibitor ZSTK474, p110α BYL719 inhibitor and the dual p110γ/p110δ inhibitor IPI145. The effects of single drugs and of several drug combinations were analyzed to assess cytotoxicity by MTS assays, apoptosis and autophagy by flow cytometry and Western blot, as well as the phosphorylation status of the pathway. ZSTK474, BYL719 and IPI145 administered in combination with imatinib, nilotinib and GZD824 for 48 h, decreased cell viability, induced apoptosis and autophagy in a marked synergistic manner. These findings suggest that selected PI3K isoform inhibitors used in combination with anti Bcr-Abl drugs may be an attractive novel therapeutic intervention in Ph+ B-ALL.
    URI
    http://hdl.handle.net/10342/8257
    Date
    2017-02-20
    Citation:
    APA:
    Ultimo, Simona, & Simioni, Carolina, & Martelli, Alberto M., & Zauli, Giorgio, & Evangelisti, Camilla, & Celeghini, Claudio, & McCubrey, James A., & Marisi, Giorgia, & Ulivi, Paola, & Capitani, Silvano, & Neri, Luca M.. (February 2017). PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, (8:14), p.23213-23227. Retrieved from http://hdl.handle.net/10342/8257

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Ultimo, Simona, and Simioni, Carolina, and Martelli, Alberto M., and Zauli, Giorgio, and Evangelisti, Camilla, and Celeghini, Claudio, and McCubrey, James A., and Marisi, Giorgia, and Ulivi, Paola, and Capitani, Silvano, and Neri, Luca M.. "PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines". Oncotarget. 8:14. (23213-23227.), February 2017. March 01, 2021. http://hdl.handle.net/10342/8257.
    Chicago:
    Ultimo, Simona and Simioni, Carolina and Martelli, Alberto M. and Zauli, Giorgio and Evangelisti, Camilla and Celeghini, Claudio and McCubrey, James A. and Marisi, Giorgia and Ulivi, Paola and Capitani, Silvano and Neri, Luca M., "PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines," Oncotarget 8, no. 14 (February 2017), http://hdl.handle.net/10342/8257 (accessed March 01, 2021).
    AMA:
    Ultimo, Simona, Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Evangelisti, Camilla, Celeghini, Claudio, McCubrey, James A., Marisi, Giorgia, Ulivi, Paola, Capitani, Silvano, Neri, Luca M.. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget. February 2017; 8(14) 23213-23227. http://hdl.handle.net/10342/8257. Accessed March 01, 2021.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback